Report of Foreign Issuer (6-k)

SINOVAC BIOTECH LTD.

Consolidated Statements of Comprehensive Income (loss)

For the three and six months ended June 30, 2015 and 2014

(Unaudited)

(Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of Aug 2015

--------------

Commission File Number: 001-32371

----------

SINOVAC BIOTECH LTD.

No. 39 Shangdi Xi Road

Haidian District

Beijing 100085, People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ___X____ Form 40-F _________

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):________________

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):________________

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SINOVAC BIOTECH LTD.

By: /s/ Weidong Yin

Name: Weidong Yin

Title: Chairman and Chief Executive Officer

Date: Aug 13, 2015

Exhibit Index

Exhibit 99.1 – Press Release

Exhibit 99.2 – Press Release

Exhibit 99.3 – Press Release

Exhibit 99.1

Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results

Date: 2015-08-04

Pageview: 1308

BEIJING, August 4, 2015 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter, ended June 30, 2015, after market close on Wednesday, August 12, 2015. The Company will host a conference call on Thursday, August 13, 2015, at 8:00 a.m. EDT (Thursday, August 13, 2015 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-9039 (USA) or 1-201-689-8470 (International). A replay of the call will be available from 11 a.m. EDT on August 13, 2015 through August 27, 2015. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and reference the replay pin number 13616892.

A live audio webcast of the call will also be available on the Investor Relations section of the Company’s website at www.sinovac.com. A webcast replay will be available on the Company’s website for 30 days following the call.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac has filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus 71 vaccine, having been proven effective in preventing hand, foot and mouth disease in infants and children during its Phase III clinical trial. The Company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mexico, Mongolia, Nepal, and the Philippines, and was recently granted a license to commercialize its hepatitis A vaccine in Chile. For more information, please visit the Company's website at www.sinovac.com.

Contact

Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com

ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com

Katherine Knight

Phone: +1 (646) 277-1276

Email: katherine.knight@icrinc.com

Exhibit 99.2 Press Release

Sinovac Announces Results of 2015 Annual General Meeting of Shareholders

Date: 2015-08-11

Pageview: 447

BEIJING, August 11, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC. The required quorum, a majority of the common shares outstanding, was voted by proxy.

The Company's shareholders approved the following proposals:

The re-election of Weidong Yin, Yuk Lam Lo, Simon Anderson, Kenneth Lee and Meng Mei as the Company's directors until the next annual meeting of shareholders and or until their successors are duly elected;

The audited consolidated financial statements of the Company for the financial year ended December 31, 2014 together with the Report of Independent Registered Public Accounting Firm thereon and the notes thereto;

The appointment of Ernst & Young Hua Ming LLP as the independent auditor of the Company for the fiscal year ending December 31, 2015 and to authorize the directors of the Company to fix such independent auditor's remuneration.

About Sinovac

Contact

Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com

ICR Inc.
Bill Zima
U.S: +1-646-308-1707
Email: william.zima@icrinc.com

Exhibit 99.3 Press Release

Sinovac Reports Unaudited Second Quarter Financial Results

-- Conference call scheduled for Thursday, August 13, 2015 at 8:00 AM ET

Date: 2015-08-13

Pageview: 254

BEIJING, Aug.12, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2015.

Second Quarter 2015 Financial Highlights
(compared to the second quarter of 2014)

Quarterly sales were $18.5 million, an increase of 53.1% from $12.1 million in the prior year period.

Gross profit was $15.1 million, an increase of 66.6% from $9.1 million in the prior year period.

Gross margin was 81.6%, compared to 75.0% in the prior year period.

Net income attributable to common shareholders was $2.3 million, or $0.04 per basic and diluted share, compared to net loss attributable to common shareholders of $2.2 million, or $(0.04) per basic and diluted share, in the second quarter of 2014.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "I am very pleased to announce our strong sales and profitability during the second quarter. We continue to execute our strategy to drive sales while maintaining tight control over our operating costs. Although the general market environment remains the same as prior quarters, our sales results in the second quarter exemplify our team's ability to adjust to challenging market dynamics."

Mr. Yin continued, "Additionally, we continue to move forward in the approval process for our EV71 vaccine candidate. During July and August, CFDA inspectors have been conducting the site and GMP inspections of our manufacturing facility. The site inspection was completed last week and will be followed by sample testing. Our projected timing for EV71 commercialization remains unchanged. "

Business Update

EV71 vaccine. The China Food and Drug Administration (CFDA) has completed a site inspection and GMP inspection of the Company's EV71 vaccine manufacturing facility, which will be followed by sample testing. Once the results of the inspection are available and the sample vaccine has passed the required testing, the CFDA will conduct a comprehensive review of the vaccine. Upon approval, the CFDA will then issue the new drug certificate, and production and GMP licenses. The Company expects to be able to bring its first commercial batch of the EV71 vaccine to market approximately four months after beginning commercial production. The Company received its site inspection notification in May of 2015.

Unaudited Financial Results for Second Quarter 2015

	2015 Q2		% of Sales			2014 Q2		% of Sales
(In USD'000 except percentage data)
Hepatitis A vaccine– Healive		8,462		45.7	%		5,113		42.3	%
Hepatitis A&B vaccine – Bilive		9,216		49.8	%		6,439		53.3	%
Hepatitis vaccines subtotal		17,678		95.5	%		11,552		95.6	%
Influenza vaccine- Anflu		526		2.8	%		-		-
Animal Rabies vaccine- Rabend		18		0.1	%		18		0.1	%
Mumps vaccine		287		1.6	%		520		4.3	%
Regular sales		18,509		100.0	%		12,090		100.0	%
H5N1		-		-			-		-
Total sales		18,509		100.0	%		12,090		100.0	%
Cost of goods sold		3,407		18.4	%		3,025		25.0	%
Gross profit		15,102		81.6	%		9,065		75.0	%

In the second quarter of 2015, total sales were $18.5 million, an increase of 53.1% from $12.1 million during the same period of 2014. The sales increase is mainly attributable to increased sales of Healive and Bilive into the private pay market, and supported by increased sales into the public market as well.

Gross profit was $15.1 million in the second quarter of 2015, compared to $9.1 million in the prior year period. Gross margin increased to 81.6% from 75.0% in the prior year period. The gross margin expansion was primarily due to higher average selling prices of the Company's hepatitis vaccines in the private pay market and a lower inventory provision compared to the comparative quarter.

Selling, general and administrative expenses in the second quarter of 2015 were $9.2 million, compared to $8.6 million in the same period of 2014. This increase was mainly due to increased G&A expenses associated with the trial production of the EV71 vaccine for the site inspection.

R&D expenses in the second quarter of 2015 were $2.2 million, compared to $3.3 million in the same period of 2014. This decrease is primarily attributable to an entrance fee incurred after the signing of the licensing agreement of sIPV production technology in the second quarter of 2014 and the purchase of the virus seeds for its sIPV candidate during the same period.

Net income attributable to common shareholders for the second quarter of 2015 was $2.3 million, or $ 0.04 per basic and diluted share, compared to a net loss attributable to common shareholders of $2.2 million, or $(0.04) per basic and diluted share, in the same period last year.

Unaudited Financial Results for First Half of 2015

- (In USD'000 except percentage data)	2015 H1		% of Sales			2014 H1		% of Sales
Hepatitis A vaccine – Healive		11,385		41.0	%		11,552		45.1	%
Hepatitis A&B vaccine – Bilive		14,271		51.4	%		12,437		48.5	%
Hepatitis vaccines subtotal		25,656		92.4	%		23,989		93.6	%
Influenza vaccine - Anflu		1,112		4.0	%		61		0.2	%
Animal Rabies vaccine - Rabend		80		0.3	%		44		0.2	%
Mumps vaccine		930		3.3	%		1,440		5.6	%
Regular sales		27,778		100.0	%		25,534		99.6	%

H5N1		-		-			102		0.4	%
Total sales		27,778		100.0	%		25,636		100.0	%
Cost of goods sold		5,841		21.0	%		6,303		24.6	%

Gross profit		21,937		79.0	%		19,333		75.4	%

Total sales for the first half of 2015 were $27.8 million, an increase of 8.4% from $25.6 million in the same period of 2014. The increase is primarily due to increased sales of Bilive into the private pay market.

Gross profit in the first half of 2015 was $21.9 million, an increase of 13.5% from $19.3 million in the same period of 2014. Gross margin was 79.0% in the first half of 2015, compared to 75.4% in the same period of 2014.

Selling, general and administrative expenses in the first half of 2015 were $16.1 million, consistent with $16.4 million in the same period of 2014.

R&D expenses in the first half of 2015 were $4.4 million, compared to $5.0 million in the same period of 2014. In the first half of 2015, the R&D expenses incurred by the Company is mainly attributable to the phase III clinical trial on PPV. Instead, in the first half of 2014, a substantial portion of the Company's R&D expenses were related to its sIPV program as explained above.

Net income attributable to common shareholders in the first half of 2015 was $20,000, or $0.00 per basic and diluted share, compared to a net loss of $2.2 million, or $(0.04) per basic and diluted share, in the same period of 2014.

As of June 30, 2015, cash and cash equivalents totaled $64.8 million, compared to $91.5 million as of December 31, 2014. Net cash used in operating activities was $7.8 million in the first half of 2015. Net cash used in investing activities was $2.8 million, which was primarily used for the purchase of property, plant and equipment. Net cash used in financing activities was $16.1 million during the first half of 2015, representing loan proceeds of $12.0 million offset by loan repayments of $28.5 million. As of June 30, 2015, the Company had $32.6 million of bank loans due within one year. When appropriate, the Company will seek new commercial bank loans to finance the commercialization of pipeline products, as well as for other operational purposes.

Conference Call Details

Sinovac will host a conference call on Thursday, August 13, 2015 at 8:00 a.m. ET (August 13, 2015 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments. To access the conference call, please dial 1-877-407-9039 (USA) or 1-201-689-8470 (International). A replay of the call will be available from 11:00 a.m. ET on August 13, 2015 through August 27, 2015. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and reference the replay pin number 13616892.

A live audio webcast of the call will also be available on the Investor Relations section of the Company's website at www.sinovac.com. A webcast replay will be available on the Company's website for 30 days following the call.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac has filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus 71 vaccine, having been proven effective in preventing hand, foot and mouth disease in infants and children during its phase III clinical trial. The Company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mexico, Mongolia, Nepal, and the Philippines, and was recently granted a license to commercialize its hepatitis A vaccine in Chile. For more information, please visit the Company's website at www.Sinovac.com .

Contact

Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com

ICR Inc.
Bill Zima
U.S: +1 (646) 308-1707
Email: william.zima@icrinc.com

Katherine Knight
Phone: +1 (646) 277-1276
Email: katherine.knight@icrinc.com

SINOVAC BIOTECH LTD.
Consolidated Balance sheets
As of June 30, 2015 and December 31, 2014
(Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data)


Current assets	June 30, 2015			December 31,2014

Cash and cash equivalents		64,756			91,518
Accounts receivable – net		44,144			40,757
Inventories		23,228			18,832
Prepaid expenses and deposits		1,154			1,430
Deferred tax assets		1,669			2,266
Total current assets		134,951			154,803

Property, plant and equipment		67,814			68,417
Prepaid land lease payments		10,275			10,405
Long-term inventories		2,650			2,648
Long-term prepaid expenses		-			3
Prepayments for acquisition of equipment		1,398			1,387
Deferred tax assets		445			515
Licenses		176			352
Total assets		217,709			238,530

Current liabilities
Short-term bank loans and current portion of long-term debt		32,640			47,375
Loan from a non-controlling shareholder		2,595			2,595
Accounts payable and accrued liabilities		19,565			23,237
Income tax payable		750			1,101
Deferred revenue		3,893			4,996
Deferred government grants		904			530
Total current liabilities		60,347			79,834

Deferred government grants		6,463			7,494
Long-term debt		-			1,803
Deferred revenue		7,197			7,191
Other non-current liabilities		479			482
Total long term liabilities		14,139			16,970

Total liabilities		74,486			96,804

Commitments and contingencies
Equity
Preferred stock		-			-
Common stock		56			56
Additional paid-in capital		109,073			108,243
Accumulated other comprehensive income		12,065			12,022
Statutory surplus reserves		12,627			12,627
Accumulated deficit		(6,364	)		(6,384	)
Total shareholders' equity		127,457			126,564

Non-controlling interests		15,766			15,162
Total equity		143,223			141,726
Total liabilities and equity		217,709			238,530


	Three months ended June 30						Six months ended June 30
	2015			2014			2015			2014
Sales		18,509			12,090			27,778			25,636
Cost of sales		3,407			3,025			5,841			6,303
Gross profit		15,102			9,065			21,937			19,333

Selling, general and administrative expenses		9,172			8,589			16,093			16,381
Provision for doubtful accounts		173			132			84			294
Research and development expenses		2,221			3,265			4,433			4,967
Loss (gain) on disposal and impairment of property, plant and equipment		(24	)		29			(24	)		29
Government grants recognized in income		(437	)		-			(443	)		-
Total operating expenses		11,105			12,015			20,143			21,671
Operating income (loss)		3,997			(2,950	)		1,794			(2,338	)

Interest and financing expenses		(421	)		(832	)		(1,009	)		(1,582	)
Interest income		288			765			715			1,545
Other income		28			71			103			217
Income (loss) before income taxes and non-controlling interests		3,892			(2,946	)		1,603			(2,158	)
Income tax expense		(440	)		(76	)		(991	)		(423	)
Net Income (loss)		3,452			(3,022	)		612			(2,581	)
Less: (Income) loss attributable to the non-controlling interests		(1,181	)		774			(592	)		337
Net Income (loss) attributable to shareholders of Sinovac		2,271			(2,248	)		20			(2,244	)

Other comprehensive income (loss), net of tax of nil
Foreign currency translation adjustments		(11	)		(319	)		55			(2,403	)
Total comprehensive income (loss)		3,441			(3,341	)		667			(4,984	)
Less: comprehensive (income) loss attributable to non-controlling interests		(1,186	)		738			(604	)		638
Comprehensive income (loss) attributable to shareholders of Sinovac		2,255			(2,603	)		63			(4,346	)

Weighted average number of shares of common stock outstanding
Basic		56,019,451			55,663,566			55,974,252			55,625,509
Diluted		56,187,591			55,663,566			56,219,495			55,625,509

Earning (loss) per share
Basic		0.04			(0.04	)		0.00			(0.04	)
Diluted		0.04			(0.04	)		0.00			(0.04	)

SINOVAC BIOTECH LTD.
Consolidated Statements of Cash Flows
For the three and six months ended June 30, 2015 and 2014
(Unaudited)
(Expressed in thousands of U.S. Dollars)

	Three months ended						Six months ended
	June 30						June 30
	2015			2014			2015			2014
Cash flows provided by (used in) operating activities
Net income (loss)	$	3,452		$	(3,022	)	$	612		$	(2,581	)
Adjustments to reconcile net income (loss) to net cash
Used in operating activities:
- deferred income taxes		165			58			699			369
- stock-based compensation		208			71			321			143
- inventory provision		521			321			566			542
- provision for doubtful accounts		173			132			84			294
- loss (gain) on disposal and impairment of equipment		(24	)		29			(24	)		29
- government grants recognized in income		(437	)		-			(443	)		-
- depreciation of property, plant and equipment and amortization of license		1,759			1,903			3,451			4,534
- amortization of the prepaid land lease payments		68			65			137			132
- accretion expenses		30			28			59			55
Changes in:
- accounts receivable		(1,770	)		1,327			(3,613	)		(3,654	)
- inventories		(3,544	)		(4,905	)		(5,086	)		(7,784	)
- income tax payable		(382	)		-			(382	)		-
- prepaid expenses and deposits		(143	)		234			521			(348	)
- deferred revenue		(1,104	)		33			(1,104	)		(685	)
- accounts payable and accrued liabilities		1,446			(1,889	)		(3,578	)		(2,459	)

Net cash provided by (used in) operating activities		418			(5,615	)		(7,780	)		(11,413	)

Cash flows provided by (used in) financing activities
- Proceeds from bank loans		11,154			3,182			11,956			8,917
- Repayments of bank loans		(9,138	)		(6,084	)		(28,541	)		(8,542	)
- Proceeds from issuance of common stock,
net of share issuance costs		237			147			500			252
- Proceeds from shares subscribed		9			31			9			80
- Government grants received		6			185			9			185

Net cash provided by (used in) financing activities		2,268			(2,539	)		(16,067	)		892

Cash flows used in investing activities
- Acquisition of property, plant and equipment		(1,064	)		(3,479	)		(2,845	)		(5,683	)

Net cash used in investing activities		(1,064	)		(3,479	)		(2,845	)		(5,683	)

Exchange gain (loss) on cash and cash equivalents		64			(385	)		(70	)		(1,404	)

Increase (decrease) in cash and cash equivalents		1,686			(12,018	)		(26,762	)		(17,608	)

Cash and cash equivalents, beginning of period		63,070			101,652			91,518			107,242

Cash and cash equivalents, end of period	$	64,756		$	89,634		$	64,756		$	89,634